Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Steroidogenesis Inhibitors (STGI) -- Ignore unavailable to you. Want to Upgrade?

To: SCOOBEY-DO who wrote (124)	7/28/1999 1:29:00 PM
From: Jim Burnham	Read Replies (1) \| Respond to of 294

I really feel good about this stock. I love the fact that the drug is based on Procaine. A tried and true drug. I'll bet this drug gets fast tracked through the FDA. I just can't get off of the Brazil clinicals. 60% mortality with current drugs. 33% mortality with current drugs and ANTICORT. 4% mortality with ANTICORT alone. Plus the estimated cost of $80/month. Third world countries will be buying it by the boat load. My predictions: September 99 - Romanian trials are successful - Deal with Pashua is finalized - $8-$10 per share November 99 - Trials for cancer announced - Trials for depression announced - $10-$15 per share December 99 - Romanian approval - ANTICORT Fast Tracked - $15-$20 per share January 00 - Pashua begins production and sales of ANTICORT. February 00 - Royalty checks start rolling in. - $20-$25 per share March 00 - FDA trials completed successfully May 00 - FDA approval - Canadian Trials finish successfully - $75-$100 per share